Current chemotherapeutic possibilities in the treatment of colorectal cancer

B. van Triest, C. J. van Groeningen, H. M. Pinedo

Research output: Contribution to journalArticle

Abstract

To date, the best treatment modality for colorectal cancer is a surgical excision of the primary tumour. Adjuvant therapy can be added to the surgical treatment and can consist of adjuvant chemo-, immuno- or radiotherapy. In the U.S.A., adjuvant chemotherapy with 5-fluorouracil (5FU) and levamisole is advocated as standard treatment for patients with localised poor risk (Dukes stage C) colon cancer. Not every clinician is convinced of the usefulness of adjuvant chemotherapy. Therefore, confirmatory clinical trials are still ongoing to compare no adjuvant treatment with SFU/levamisole adjuvant treatment. Treatment with SFU/leucovorin has been shown to be effective as adjuvant therapy. In rectal cancer, radiotherapy can be added to the primary surgical treatment. It is still unproven whether radiotherapy should be given pre-, peri, or postoperatively, and whether chemotherapy should be added to this multimodality regimen. If chemotherapy is applied as a radio-sensitiser, a continuous infusion is preferable to daily bolus injection. Much effort has been put into the improvement of the response rate of 10-15% 5FU, used as a single agent in the treatment of advanced colorectal cancer. Biochemical modulation of 5FU with leucovorin and interferon, different schedules of 5FU administration and hepatic arterial therapy have all been attempted. Higher response rates have been reported with these treatment modalities, unfortunately without improvement of survival, except for the intra-arterial approach. Recently, two new drugs have shown efficacy in the treatment of advanced colorectal cancer. A phase II trial with Tomudex (ZD1694), a new antifolate thymidylate synthase inhibitor, produced a response rate of 25% in patients with advanced colorectal cancer. A phase II trial with CPT-11, a topoisomerase I inhibitor, produced a response rate of 27% in patients with advanced disease and 25% response in patients with prior chemotherapy.

Original languageEnglish (US)
Pages (from-to)1193-1197
Number of pages5
JournalEuropean Journal of Cancer
Volume31
Issue number7-8
DOIs
StatePublished - 1995
Externally publishedYes

Fingerprint

Colorectal Neoplasms
Fluorouracil
Therapeutics
Levamisole
irinotecan
Radiotherapy
Leucovorin
Adjuvant Chemotherapy
Drug Therapy
Topoisomerase I Inhibitors
Folic Acid Antagonists
Thymidylate Synthase
Rectal Neoplasms
Radio
Immunotherapy
Colonic Neoplasms
Interferons
Appointments and Schedules
Clinical Trials
Injections

Keywords

  • chemotherapy
  • colorectal cancer

ASJC Scopus subject areas

  • Cancer Research
  • Oncology
  • Hematology

Cite this

Current chemotherapeutic possibilities in the treatment of colorectal cancer. / van Triest, B.; van Groeningen, C. J.; Pinedo, H. M.

In: European Journal of Cancer, Vol. 31, No. 7-8, 1995, p. 1193-1197.

Research output: Contribution to journalArticle

van Triest, B. ; van Groeningen, C. J. ; Pinedo, H. M. / Current chemotherapeutic possibilities in the treatment of colorectal cancer. In: European Journal of Cancer. 1995 ; Vol. 31, No. 7-8. pp. 1193-1197.
@article{e109f62e4ac349e7a82e9754b25379a7,
title = "Current chemotherapeutic possibilities in the treatment of colorectal cancer",
abstract = "To date, the best treatment modality for colorectal cancer is a surgical excision of the primary tumour. Adjuvant therapy can be added to the surgical treatment and can consist of adjuvant chemo-, immuno- or radiotherapy. In the U.S.A., adjuvant chemotherapy with 5-fluorouracil (5FU) and levamisole is advocated as standard treatment for patients with localised poor risk (Dukes stage C) colon cancer. Not every clinician is convinced of the usefulness of adjuvant chemotherapy. Therefore, confirmatory clinical trials are still ongoing to compare no adjuvant treatment with SFU/levamisole adjuvant treatment. Treatment with SFU/leucovorin has been shown to be effective as adjuvant therapy. In rectal cancer, radiotherapy can be added to the primary surgical treatment. It is still unproven whether radiotherapy should be given pre-, peri, or postoperatively, and whether chemotherapy should be added to this multimodality regimen. If chemotherapy is applied as a radio-sensitiser, a continuous infusion is preferable to daily bolus injection. Much effort has been put into the improvement of the response rate of 10-15{\%} 5FU, used as a single agent in the treatment of advanced colorectal cancer. Biochemical modulation of 5FU with leucovorin and interferon, different schedules of 5FU administration and hepatic arterial therapy have all been attempted. Higher response rates have been reported with these treatment modalities, unfortunately without improvement of survival, except for the intra-arterial approach. Recently, two new drugs have shown efficacy in the treatment of advanced colorectal cancer. A phase II trial with Tomudex (ZD1694), a new antifolate thymidylate synthase inhibitor, produced a response rate of 25{\%} in patients with advanced colorectal cancer. A phase II trial with CPT-11, a topoisomerase I inhibitor, produced a response rate of 27{\%} in patients with advanced disease and 25{\%} response in patients with prior chemotherapy.",
keywords = "chemotherapy, colorectal cancer",
author = "{van Triest}, B. and {van Groeningen}, {C. J.} and Pinedo, {H. M.}",
year = "1995",
doi = "10.1016/0959-8049(95)00161-B",
language = "English (US)",
volume = "31",
pages = "1193--1197",
journal = "European Journal of Cancer",
issn = "0959-8049",
publisher = "Elsevier Limited",
number = "7-8",

}

TY - JOUR

T1 - Current chemotherapeutic possibilities in the treatment of colorectal cancer

AU - van Triest, B.

AU - van Groeningen, C. J.

AU - Pinedo, H. M.

PY - 1995

Y1 - 1995

N2 - To date, the best treatment modality for colorectal cancer is a surgical excision of the primary tumour. Adjuvant therapy can be added to the surgical treatment and can consist of adjuvant chemo-, immuno- or radiotherapy. In the U.S.A., adjuvant chemotherapy with 5-fluorouracil (5FU) and levamisole is advocated as standard treatment for patients with localised poor risk (Dukes stage C) colon cancer. Not every clinician is convinced of the usefulness of adjuvant chemotherapy. Therefore, confirmatory clinical trials are still ongoing to compare no adjuvant treatment with SFU/levamisole adjuvant treatment. Treatment with SFU/leucovorin has been shown to be effective as adjuvant therapy. In rectal cancer, radiotherapy can be added to the primary surgical treatment. It is still unproven whether radiotherapy should be given pre-, peri, or postoperatively, and whether chemotherapy should be added to this multimodality regimen. If chemotherapy is applied as a radio-sensitiser, a continuous infusion is preferable to daily bolus injection. Much effort has been put into the improvement of the response rate of 10-15% 5FU, used as a single agent in the treatment of advanced colorectal cancer. Biochemical modulation of 5FU with leucovorin and interferon, different schedules of 5FU administration and hepatic arterial therapy have all been attempted. Higher response rates have been reported with these treatment modalities, unfortunately without improvement of survival, except for the intra-arterial approach. Recently, two new drugs have shown efficacy in the treatment of advanced colorectal cancer. A phase II trial with Tomudex (ZD1694), a new antifolate thymidylate synthase inhibitor, produced a response rate of 25% in patients with advanced colorectal cancer. A phase II trial with CPT-11, a topoisomerase I inhibitor, produced a response rate of 27% in patients with advanced disease and 25% response in patients with prior chemotherapy.

AB - To date, the best treatment modality for colorectal cancer is a surgical excision of the primary tumour. Adjuvant therapy can be added to the surgical treatment and can consist of adjuvant chemo-, immuno- or radiotherapy. In the U.S.A., adjuvant chemotherapy with 5-fluorouracil (5FU) and levamisole is advocated as standard treatment for patients with localised poor risk (Dukes stage C) colon cancer. Not every clinician is convinced of the usefulness of adjuvant chemotherapy. Therefore, confirmatory clinical trials are still ongoing to compare no adjuvant treatment with SFU/levamisole adjuvant treatment. Treatment with SFU/leucovorin has been shown to be effective as adjuvant therapy. In rectal cancer, radiotherapy can be added to the primary surgical treatment. It is still unproven whether radiotherapy should be given pre-, peri, or postoperatively, and whether chemotherapy should be added to this multimodality regimen. If chemotherapy is applied as a radio-sensitiser, a continuous infusion is preferable to daily bolus injection. Much effort has been put into the improvement of the response rate of 10-15% 5FU, used as a single agent in the treatment of advanced colorectal cancer. Biochemical modulation of 5FU with leucovorin and interferon, different schedules of 5FU administration and hepatic arterial therapy have all been attempted. Higher response rates have been reported with these treatment modalities, unfortunately without improvement of survival, except for the intra-arterial approach. Recently, two new drugs have shown efficacy in the treatment of advanced colorectal cancer. A phase II trial with Tomudex (ZD1694), a new antifolate thymidylate synthase inhibitor, produced a response rate of 25% in patients with advanced colorectal cancer. A phase II trial with CPT-11, a topoisomerase I inhibitor, produced a response rate of 27% in patients with advanced disease and 25% response in patients with prior chemotherapy.

KW - chemotherapy

KW - colorectal cancer

UR - http://www.scopus.com/inward/record.url?scp=0029143511&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029143511&partnerID=8YFLogxK

U2 - 10.1016/0959-8049(95)00161-B

DO - 10.1016/0959-8049(95)00161-B

M3 - Article

C2 - 7577020

AN - SCOPUS:0029143511

VL - 31

SP - 1193

EP - 1197

JO - European Journal of Cancer

JF - European Journal of Cancer

SN - 0959-8049

IS - 7-8

ER -